Table 2.
Agonists and antagonists of β3-adrenoceptors (ARs).
| β3-Agonist | Chemical name |
|---|---|
| BRL 26830A | methyl 4-[2-[[2-hydroxy-2-phenethyl]amino]propyl]benzoate-2-butanedioate |
| BRL 35135 | methyl 4-[2-[2-hydroxy-2-[3-chlorophenyl]ethylamino] propyl] phenoxyacetate |
| BRL 37344 | 4-[-[[2-hydroxy-[3-chlorophenyl] ethyl]- amino] propyl] phenoxyacetate |
| CGP 12177 | 4-[3-t-butylamino-2-hydroxypropoxy]benzimidazol-2-one |
| CGP 20712A | 2-hydroxy-5-[2-[{2-hydroxy-3-[4-[1-methyl-4-trifluoromethyl-2-imidazolyl]phenoxy]propyl}amino]ethoxy] benzamide |
| CL 316243 | disodium[R,R]-5-[2[[2-[3-chlorophenyl]-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate |
| FR-149175 | ethyl-[[S]-8-[[R]-2-[3-chlorophenyl]-2-hydroxyethylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yloxy]acetate monohydrochloride monohydrate |
| ICI 198157 | methyl [4-[2-[[2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]acetate |
| ICI D7114 | [S]-4-[2-hydroxy-3-phenoxypropylaminoethoxy]-N-[2-methoxyethyl]phenoxyacetamide |
| L 742,791 | [S]-N-[4-[2-{[3-[4-hydroxyphenoxy]-2-hydroxypropyl]amino}ethyl]phenyl]-4-iodobenzenesulfonamide |
| L 750355 | 3-pyridyloxypropanoloamine derivative |
| L755,507 | 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy) propyl] amino]ethyl]phenyl]-benzenesulfonamide |
| L 770,644 | [R]-4-[4-[3-cyclopentylpropyl]-4,5-dihydro-5-oxo-1 H-tetrazol-1-yl]-N-[4-[2-[[2-hydroxy-2-[3-pyridinyl]ethyl]amino] ethyl]phenyl]- benzenesulfonamide |
| L 796568 | [R]-N -[4-[2-[[2-hydroxy-2-[3-pyridinyl]ethyl]amino]ethyl]-phenyl]-4-[4-[4-[trifluoromethyl]phenyl]thiazol-2-yl]-benzenesulfonamide, dihydrochloride |
| LY 79771 | [R-[R*, S*]] alpha-[[[3-[4-hydroxyphenyl]-1-methylpropyl]amino]methyl]benzenemethanol |
| RO363 | [-]-1-[3,4-dimethoxyphenethylamino]-3-[3,4-dihdroxyphenoxy]-2-propanol] oxalate |
| SB 251023 | [4-[1-{2-[S]-hydroxy-3-[4-hydroxyphenoxy]-propylamino} cyclopentyl methyl]phenoxymethyl]phenylphosphonic acid lithium salt |
| SR 58611 | [RS]-N-[[25]-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronapth-2-yl]-[2R]-2-[3-chlorophenyl]-2-hydroxyethanamine hydrochloride |
| SR 58611A | [N2S]-7-carbethoxymethoxy-1,2,3,4-tetrahydronaphth-2-yl-[2R]-2-hydroxy-2-chlorophenyl ethanamine hydrochloride |
| SR 59104A | N-[[6-hydroxy-1,2,3,4-tetrahydronaphthalen-[2R]-2-yl]methyl]-[2R]-2-hydroxy-2-[3-chlorophenyl]ethanamine hydrochloride |
| SR 59119A | N-[[7-methoxy-1,2,3,4-tetrahydronaphthalen-[2R]-2-yl]methyl]-[2R]-2-hydroxy-2-[3-chlorophenyl]ethanamine hydrochloride |
| ZD2079 | 4-[2-[[(2R)-2-Hydroxy-2-phenylethyl] amino]ethoxy]-benzeneacetic acid hydrochloride |
| ZD 7114 | [S]-4-[2-hydroxy-3-phenoxypropylaminoethoxy]-N-[2-methoxyethyl]phenoxyacetamide |
| ZM 215001 | [S]-4-[2-hydroxy-3-phenoxy-propylamino-ethoxy] phenoxyacetic acid [R]-N-[4-[2-[[2-hydroxy-2-[3-pyridinyl]ethyl]amino]ethyl]phenyl]-1-[4-octylthiazol-2-yl]-5-indolinesulfonamide |
| β3-Antagonist | Chemical name |
| L 748328 | [S]-N-[4-[2-{[3-[3-{aminosulfonyl}phenoxy]-2-hydroxypropyl]-amino}ethyl] phenyl]benzenesulfonamide |
| SR 59230A | 3-[2-ethylphenoxy]-1[1 S]-1,2,3,4-tetrahydronaphth-1-ylaminol-[2S]2-propanol oxalate |